Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. The trial is also expected to be conducted in Sweden, Poland, Latvia, Estonia, Croatia, and Bulgaria. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
Every year on the 11th of October, the International Day […]
Crown CRO supports international students by offering mentoring to those interested in Clinical Research
The University of Helsinki has started a mentoring program (HelsinkiUNI […]
The COVID-19 pandemic shocked us when we least expected it […]
It has been a privilege to operate in the clinical […]
Crown CRO is proud to be part of the CoroPrevention Clinical Trial – a unique opportunity to evaluate personalized prevention in CHD.
Coronary Heart Disease (CHD) affects both men and women and […]